Andrew J. Armstrong, MD

Articles

Metastatic CRPC: Clinical Pearls and Practical Advice

May 19th 2022

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.

Emerging Targeted Therapies in mCRPC

May 12th 2022

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Defining Unmet Needs in the Management of mCRPC

May 12th 2022

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Ongoing PSMA-Targeted Radioligand Trials in mCRPC

May 5th 2022

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Metastatic CRPC: Considerations for Radiotherapy

May 5th 2022

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

Potential Role of Lu-PSMA-617 in mCRPC

April 28th 2022

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

VISION Trial: Lu-PSMA-617 in mCRPC

April 28th 2022

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Dr. Armstrong on Updated Results of the ARCHES Trial in mHSPC

April 26th 2022

Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Role of Radium-223 in Treating mCRPC

April 21st 2022

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Patient Factors in Selecting Therapy for mCRPC

April 21st 2022

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC Treatment Armamentarium

April 14th 2022

A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.

Role of Novel Imaging in Prostate Cancer

April 14th 2022

A brief discussion on how novel imaging strategies are being used to inform the treatment of patients with prostate cancer.

Phenotypic Biomarkers in the Management of Prostate Cancer

April 6th 2022

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Background on Prostate Cancer and Biomarker Testing

April 6th 2022

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Dr. Armstrong on Findings From a Post-Hoc Analysis of the ARCHES Trial in mHSPC

February 17th 2022

Andrew J. Armstrong, MD, MSc, discusses findings from a post-hoc analysis of the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

ARCHES Final OS Analysis in mHSPC

October 15th 2021

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Dr. Armstrong on the utility of PARP Inhibitors in Mutated Prostate Cancer

April 30th 2020

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

April 10th 2020

Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.

Dr. Armstrong on Detection of Chromosomal Defects in mCRPC

March 21st 2020

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Dr. Armstrong on the Utility of AR-V7 as a Biomarker in Prostate Cancer

March 20th 2020

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.